Compare Amphastar Pharmaceuticals Inc (AMPH) vs NetApp Inc. (NTAP) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

NetApp (NTAP) trades at $168.87, down 1.67% on the day but up significantly year-to-date, driven by strong AI infrastructure demand. The stock shows bullish technical signals with moving averages aligned positively, while fundamentals reveal robust profitability with an 18.43% net margin and consistent earnings beats. Recent news highlights partnerships and AI workload enhancements, supporting growth momentum.

Outlook remains positive with AI-driven revenue acceleration, though valuation multiples like P/E of 26.59 suggest premium pricing. Risks include competitive pressures and execution challenges in scaling AI offerings. Analyst consensus leans hold with a $167.45 target, indicating limited near-term upside from current levels.